Sponsoring Agency HHS
    POP 9/19/13 - 9/18/18 (4 years)


The Department of Health and Human Services (HHS) has the responsibility of maintaining a definitive supply of medical countermeasures - or the forward deployment of same - for use in national medical emergencies declared by the Secretary of HHS.HHS has a requirement to acquire, hold, and distribute medical countermeasures that will mitigate injuries caused by exposure to chemical threat agents, biological threat agents, and physical radiologic and nuclear exposures. In the case of exposure to radiologic or nuclear ionizing energy, the integrity and homeostasis of neutrophil number and function (i.e., neutropenia) is an early pathology that must be clinically addressed due to increased risk of infection and sepsis. The most common clinical treatment to address neutropenia is the use of Colony Stimulating Factor (CSF) as either Granulocyte (G) or Granulocyte-Macrophage (GM), also known as G-CSF or GM-CSF.

  • $171.3m Aggregate Dollars Obligated
  • $171.3m Aggregate Base & Exercised Options
  • $171.3m Aggregate Base & All Options (Ceiling)

Market Stats Related Contracts